GLASGOW, April 17, 2015 /PRNewswire/ --
The European Stroke Organisation (ESO), at the first annual
European Stroke Organisation Conference (ESOC 2015), in
Glasgow, April 17-19, is pleased to announce the release
of revolutionary medical trials and their results.
Today's sessions which featured new large clinical trials and
hot results (April 17, 10:30-12:00
and 14:00-15:00) are of significant impact to the global stroke
community. Included among the various presentations, were the
following industry studies:
PISCES - A Phase I Trial of CTX0E03 Human Neural Stem Cells
in Ischaemic Stroke
The PISCES study was the first human study of human neural stem
cells, given as an injection directly into the brain. The study
included 11 male patients with long-term disability between 6 and
60 months after a stroke. The main purpose of the study was to
determine safety. The final results are based on a minimum of 2
years of follow-up after the procedure. No cell-related adverse
effects were seen. There were small improvements in neurological
status and function in most participants, which were seen within a
short time of the procedure and maintained throughout
follow-up.
REVASCAT: Thrombectomy within 8 Hours after Symptom Onset in
Ischemic Stroke
Four centers in Catalonia, Spain, randomized 206 patients with large
anterior arterial occlusions to receive thrombectomy with the
Solitaire device in addition to medical therapy (including IV t-PA
if eligible) or medical therapy alone within 8 hours from the onset
of stroke symptoms. Thrombectomy reduced the severity of disability
over the range of the modified Rankin scale, led to higher rates of
functional independence at 90 days (43.7% vs. 28.2%; adjusted odds
ratio, 2.1; 95% CI, 1.1 to 4.0), reduced infarct size and increased
quality of life at 3 months, without differences in mortality or
symptomatic intracranial hemorrhage. REVASCAT contributes evidence
to support the efficacy of neurovascular thrombectomy in patients
with anterior circulation stroke who could be treated within 8
hours after the onset of symptoms.
Administration of Uric Acid in Acute Stroke: Results in Women
and in Patients with Hyperglycemia
Giving stroke patients uric acid (a powerful antioxidant) along
with standard clot-busting medication within 4.5 hours of first
symptoms appears safe and effective at limiting disability,
according to a recently Spanish multicenter study coordinated by
Angel Chamorro, director of the
Comprehensive Stroke Center, at Hospital Clinic in Barcelona, Spain. Although the study was not
powered to provide definitive evidence of the value of this new
treatment approach it showed highly significant benefits in
relevant subgroups which were presented at the ESOC in Glasgow by investigators of the study. Thus,
Laura Llull showed the significant
benefits obtained by women after uric acid therapy, and which were
attributed to their more limited antioxidant capacity than men.
Likewise, Sergio Amaro showed the
greater benefits obtained by patients with high blood sugar at
stroke, a situation where oxidative stress is known to be
significantly increased. According to these researchers uric acid
may have a greater role in regulating human health and is a
possible new approach to managing acute stroke that deserves
validation in a larger confirmatory study.
About ESO
The European Stroke Organisation (ESO) is a Pan-European society of
stroke researchers, national and regional stroke societies and lay
people organisations that was founded in December 2007. The aim of the ESO is to reduce
the incidence and impact of stroke by changing the ways that stroke
is viewed and treated. This can only be achieved by professional
and public education, and by making institutional changes. The ESO
provides assistance in achieving this goal and in harmonising
stroke management across the whole of Europe. The ESO's major objective is to
improve and optimise the management of stroke in Europe by providing medical education to
healthcare professionals and the lay public in Europe. By offering best practice approaches,
the ESO's goal is to harmonise stroke management in Europe. For more information, visit the
website at: http://www.eso-stroke.org.
For more information, contact:
Rachel Zeevy, Marketing Manager
Kenes Group
Tel. +41-22-9080488 Ext 525
Email. rzeevy@kenes.com